Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor   therapy: results from the British Society for Rheumatology Biologics Register

(2008) M J Harrison et al.   ANNALS OF THE RHEUMATIC DISEASES

Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis

(2008) Manuelle Viguier et al.   ARTHRITIS AND RHEUMATISM

Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate

(2008) Rachelle Buchbinder et al.   ARTHRITIS AND RHEUMATISM

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

(2008) C. Leonardi et al.   BRITISH JOURNAL OF DERMATOLOGY

Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis

(2008) Julia M. Kwan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET